Navigation Links
Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon
Date:5/7/2008

DALLAS, May 7 /PRNewswire-FirstCall/ -- Entrust, Inc. (Nasdaq: ENTU) Chairman, President and CEO Bill Conner will present at the 8th Annual State of Technology Luncheon on Thursday, May 8, at 12 p.m. CDT, at Sheraton Dallas Hotel in Dallas, Texas.

Conner will address the history of attacks on digital identities and information and how security has evolved to address the growing threats. Conner also will discuss how the cybersecurity landscape has evolved from playing on organizational fear to enabling organizations to securely conduct business with customers online, as well as the evolution of trusted government-issued identity credentials.

The Annual State of Technology Luncheon & Innovation Showcase brings together more than 700 regional technology and life science executives to focus on current issues discussed by a C-level industry keynote speaker. Expert speakers will address new proactive security technologies.

About Entrust

Entrust (Nasdaq: ENTU) secures digital identities and information for consumers, enterprises and governments in more than 1,700 organizations spanning 60 countries. Leveraging a layered security approach to address growing risks, Entrust solutions help secure the most common digital identity and information protection pain points in an organization. These include SSL, authentication, fraud detection, shared data protection and e-mail security. For information, call 888-690-2424, e-mail entrust@entrust.com or visit htt
'/>"/>

SOURCE Entrust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
2. KGI Names Kerry Howell Vice President for Advancement
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
7. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
8. CryoLife Names Philip Theodore as Vice President, General Counsel
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... March 29, 2015 Caris Life ... study data showing the presence of PD-1 ... cancer samples. Using Caris Molecular Intelligence®, the ... identified expression of programmed cell death protein-1 ... histology while its ligand (PD-L1) expression was ...
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
(Date:3/27/2015)... 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , today reported ... December 31, 2014.  The Company reported ... share, for the three months ended December 31, 2014.  ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Mass., Jan. 9, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... hepatitis C virus (HCV) development pipeline. ... of a phase I clinical trial of the Company,s ...
... 9, 2012 , Collaboration to create ... to active TB, enabling early treatment and disease outbreak prevention ... infectious disease portfolio with development of DNA-/RNA-based test that complements ... , New assay will use whole blood transcription profiling ...
... FRANCISCO, Jan. 7, 2012 Sutro Biopharma, a biopharmaceutical ... pharmaceutical properties, today announced that it has appointed James ... its newly formed scientific advisory board (SAB).  Prof. Wells ... "We have brought together two leading scientific experts in ...
Cached Biology Technology:Idenix Reports Advancement of HCV Development Pipeline 2Idenix Reports Advancement of HCV Development Pipeline 3Idenix Reports Advancement of HCV Development Pipeline 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 2QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 3QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 5QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 6QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 7Sutro Announces Newly Formed Scientific Advisory Board 2Sutro Announces Newly Formed Scientific Advisory Board 3
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year history ... Hammacher Schlemmer introduces The Eye Scanning Password Authenticator ... granting access to secure websites or sensitive data. ... travelers at international borders, the device has a small ... points of the iris, converting them into an encrypted ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... After every meal, the body must prevent the immune ... researchers report the identity of a nutrient "floodgate" that ... Their findings appear in the May 4, 2007 issue ... , The researchers found that animals lacking a protein ...
... body appears to control whether certain medications, such as ... or in inhalers for asthma, lose their effectiveness over ... the body that controls many functions, including the contraction ... conducted by Duke University Medical Center and Howard Hughes ...
... diabetic patients of the superbug MRSA - by treating ... and his team used green bottle fly larvae to ... with MRSA and found all but one were cured ... than the 28-week duration for the conventional treatment. ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Maggots rid patients of MRSA 2
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
... Pre-tested for optimal ... support the growth of ... for methylcellulose colony-forming assays ... hematopoietic cells. Not suitable ...
... RAW 264. 7 cells were cultured in DMEM ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Biology Products: